Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Reproduction ; 128(4): 395-407, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15454634

ABSTRACT

Mouse-specific immunocontraceptive peptides have been identified in mouse proteins with key roles in reproduction from sequence comparisons to other species and tested for efficacy as immunocontraceptive antigens. Peptides were derived from granulocyte-macrophage colony-stimulating factor (GMCSF), the placental 27 kDa heat-shock protein (HSP), leukemia inhibitory factor receptor (LIFR), oviduct glycoprotein (OGP), proliferin (PLF), prolactin (PRL), sperm protein SP56 and mouse zona pellucida subunits 1 and 3 (ZP1, ZP3). Fertility of female BALB/c mice was reduced after immunization with several peptides either conjugated to a carrier protein or in the form of recombinant polyepitopes. The most effective conjugated peptides (SP56, GMCSF and PRL) induced peptide-specific serum antibodies and reduced fertility by 50%. Fertility of mice was also reduced after immunization with polyepitope antigens containing up to five different peptides fused to maltose-binding protein, but antibodies were not produced against all the encoded peptides. The most effective polyepitope antigen (containing PLF, SP56, ZP1 and ZP3 peptides) reduced fertility by 50% but induced only SP56 and ZP1 antibodies. We demonstrate that lack of antibody response to a given peptide epitope (ZP3) can be overcome if repeated copies are used in the polyepitope antigen construct, but the effect varies between mouse strains. We conclude that infertility induced in mice with a range of peptide-based vaccines is dependent on antigen formulation and genetic factors but does not necessarily correlate with peptide-specific antibody levels. In light of these results, strategies to improve the efficacy of peptide-based antifertility vaccines are discussed.


Subject(s)
Contraception, Immunologic , Vaccines, Contraceptive/administration & dosage , Vaccines, Subunit/administration & dosage , Amino Acid Sequence , Animals , Antibodies/blood , Antigens/administration & dosage , Antigens/genetics , Base Sequence , Egg Proteins/immunology , Epitopes/immunology , Female , Immunoglobulin G/blood , Membrane Glycoproteins/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Molecular Sequence Data , Ovary/ultrastructure , Peptides/immunology , Receptors, Cell Surface/immunology , Vaccines, Contraceptive/genetics , Vaccines, Subunit/genetics , Zona Pellucida Glycoproteins
2.
Reproduction ; 127(3): 325-34, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15016952

ABSTRACT

Mouse PH20 (mPH20), the mouse homologue to guinea pig hyaluronidase protein PH20 (gpPH20), was used to produce contraceptive vaccines that target both sexes of mice. Previously, immunization with a female gamete antigen (the zona pellucida subunit 3 protein) delivered in a recombinant murine cytomegalovirus (MCMV), or as a purified recombinant protein, has been shown to induce infertility in female mice. There is evidence, however, that sperm protein antigens could provide broader contraceptive coverage by affecting both males and females, and the most promising has been gpPH20 when tested in a guinea pig model. Mice were therefore either inoculated with a recombinant MCMV expressing mPH20 or immunized directly with purified recombinant mPH20 protein fused to maltose-binding protein. Mice treated with either vaccine formulation developed serum antibodies that cross-reacted to a protein band of 55 kDa corresponding to mPH20 in Western blots of mouse sperm. However, there was no significant reduction in the fertility of males or females compared with control animals with either formulation. We conclude from our data that recombinant mPH20 is not a useful antigen for inclusion in immunocontraceptive vaccines that target mice.


Subject(s)
Cell Adhesion Molecules/immunology , Vaccines, Contraceptive , Animals , Cell Adhesion Molecules/genetics , Female , Fertility , Genetic Vectors/administration & dosage , Hyaluronoglucosaminidase , Male , Mice , Muromegalovirus/genetics , Recombinant Proteins/immunology , Treatment Failure , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL